Barbara M. Wirostko
( out of 107 reviews )

Barbara M. Wirostko, MD

Languages spoken: English

Clinical Locations

John A. Moran Eye Center

Salt Lake City
801-581-2352

Redstone Health Center

Park City
435-658-9200

  • Barbara M. Wirostko, MD, FARVO, treats glaucoma and comprehensive ophthalmology patients, specializes in clinical research, and advises drug development for glaucoma pharmaceutical therapies. She has specialized fellowship training in glaucoma, is a board-certified ophthalmologist, and is a Fellow of The Association of Research in Vision and Ophthalmology (ARVO).

    Her research interest is in novel glaucoma therapeutics, sustained delivery of therapeutics for ocular pathologies, and better understanding the genetics and associated systemic diseases of exfoliative syndrome, a common cause of open-angle glaucoma. As a serial entrepreneur for biotech startups, she has received millions in grants as the principal investigator (PI) for funding from the Department of Defense and National Science Foundation.

    Dr. Wirostko has scored in the top 10 percent nationwide for patient satisfaction. Her honors include Moran’s Clinical Faculty of the Year Award in 2015 and the Third Annual Distinguished Alumni Award from the Edward S. Harkness Eye Institute, Columbia University.

    Her professional and scientific experience includes serving as associate editor for Ophthalmology Glaucoma, Acta Ophthalmologica, and Journal of Glaucoma. She’s an active committee member for ARVO and a scientific advisor for the California Institute of Regenerative Medicine, The Glaucoma Foundation, and the Glaucoma Research Foundation.

    Dr. Wirostko’s numerous grants include a new two-year project funded by a BrightFocus Foundation National Glaucoma Research award of nearly $180,000. The research project, “Prognostic Factors and Predictive Markers of Progression to Exfoliation Glaucoma in Exfoliation Syndrome,” will include a multi-disciplinary team of experts. She will serve as co-PI with Karen Curtin, PhD, MStat, with the Utah Population Database.

    Get to know Dr. Wirostko by watching her profile video.

    Specialties

    Board Certification

    American Board of Ophthalmology

    Patient Rating

    5.0 /5
    ( out of 107 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety.
    Patients are de-identified for confidentiality and patient privacy.

    June 22, 2024
    REDSTONE HEALTH CENTER

    Dr. Wirostko is a consummate professional with an excellent bedside manner

    June 20, 2024
    REDSTONE HEALTH CENTER

    Dr. Wirostco is excellent and very professional.

    June 20, 2024
    REDSTONE HEALTH CENTER

    Dr. Wirostko is the best of the best.

    June 13, 2024
    REDSTONE HEALTH CENTER

    Barbara is excellent. She explains options in clear ways so that you understand.

    May 30, 2024
    REDSTONE HEALTH CENTER

    Dr Wirostko explained what she would be doing and everything went very smoothly.

    May 27, 2024
    REDSTONE HEALTH CENTER

    She was very interested in dealing with my particular conditions. Gave me clear explanations and directions for continuing care.

    May 13, 2024
    REDSTONE HEALTH CENTER

    Dr. Wirostko could not have been more generous with her time, fully explaining the purpose of each procedure done by the technician, prior to her having seen me. She spoke loudly enough for me to hear her, and willingly repeated information when asked.

    May 06, 2024
    REDSTONE HEALTH CENTER

    Dr Wirostko is an outstanding doctor. She explains my eye issues very throughly and is very compassionate and caring. I am very fortunate that she is my eye doctor.

    May 02, 2024
    REDSTONE HEALTH CENTER

    Showed concern and compassion during my visit.

    See More Patient Comments

  • Barbara M. Wirostko, MD, FARVO, treats glaucoma and comprehensive ophthalmology patients, specializes in clinical research, and advises drug development for glaucoma pharmaceutical therapies. She has specialized fellowship training in glaucoma, is a board-certified ophthalmologist, and is a Fellow of The Association of Research in Vision and Ophthalmology (ARVO).

    Her research interest is in novel glaucoma therapeutics, sustained delivery of therapeutics for ocular pathologies, and better understanding the genetics and associated systemic diseases of exfoliative syndrome, a common cause of open-angle glaucoma. As a serial entrepreneur for biotech startups, she has received millions in grants as the principal investigator (PI) for funding from the Department of Defense and National Science Foundation.

    Dr. Wirostko has scored in the top 10 percent nationwide for patient satisfaction. Her honors include Moran’s Clinical Faculty of the Year Award in 2015 and the Third Annual Distinguished Alumni Award from the Edward S. Harkness Eye Institute, Columbia University.

    Her professional and scientific experience includes serving as associate editor for Ophthalmology Glaucoma, Acta Ophthalmologica, and Journal of Glaucoma. She’s an active committee member for ARVO and a scientific advisor for the California Institute of Regenerative Medicine, The Glaucoma Foundation, and the Glaucoma Research Foundation.

    Dr. Wirostko’s numerous grants include a new two-year project funded by a BrightFocus Foundation National Glaucoma Research award of nearly $180,000. The research project, “Prognostic Factors and Predictive Markers of Progression to Exfoliation Glaucoma in Exfoliation Syndrome,” will include a multi-disciplinary team of experts. She will serve as co-PI with Karen Curtin, PhD, MStat, with the Utah Population Database.

    Get to know Dr. Wirostko by watching her profile video.

    Board Certification and Academic Information

    Academic Departments Ophthalmology & Visual Sciences -Adjunct
    Board Certification
    American Board of Ophthalmology

    Education history

    Fellowship Glaucoma - The New York Hospital, Cornell Medical Center Fellow
    Ophthalmology - Columbia Presbyterian Medical Center, Edward S. Harkness Eye Institute Resident
    Internship Hackensack Medical Center Intern
    Medicine - Columbia University M.D.
    Undergraduate Microbiology - Cornell University B.A.

    Selected Publications

    Journal Article

    1. Polski A, Long T, Stagg BC, Wirostko B (2024). Uveitis-Glaucoma-Hyphema Syndrome from Subtle Malposition of a Hydrus Microstent. J Glaucoma. (Read full article)
    2. Polski A, Liu KC, Gupta D, Grewal DS, Horns J, Wirostko BM, Stagg BC (2023). Incident glaucoma and ocular hypertension after periocular and intravitreal steroid injections: a claims-based analysis. BMJ Open Ophthalmol, 8(1). (Read full article)
    3. Delsoz M, Raja H, Madadi Y, Tang AA, Wirostko BM, Kahook MY, Yousefi S (2023). The Use of ChatGPT to Assist in Diagnosing Glaucoma Based on Clinical Case Reports. Ophthalmol Ther. (Read full article)
    4. Patil A, Conley M, Pompoco C, Paulson C, Taylor S, Swiston C, Herrick JS, Ritch R, Curtin K, Wirostko B (2022). Abdominal aortic aneurysm and exfoliation syndrome in Utah. Acta Ophthalmol, 101(4), 449-456. (Read full article)
    5. Roy Chowdhury U, Pervan-Steel CL, Sheeler R, Sookdeo HK, Rogers B, Casale R, Dosa PI, Htoo T, Wirostko BM, Fautsch MP (2023). Preclinical Pharmacokinetic Profile of Topical Ophthalmic and Intravenous Delivery of QLS-101, a Novel ATP-Sensitive Potassium Channel Opening Ocular Hypotensive Agent. J Ocul Pharmacol Ther, 39(5), 332-346. (Read full article)
    6. Patil A, Conley M, Paulson C, Pompoco C, Wallace R, Swiston RR, Curtin K, Wirostko B (2022). Abdominal aortic aneurysm and exfoliation syndrome: A literature review comparing single site findings . Acta Ophthalmol (Copenh), 101(5), 478-484.
    7. Paulson C, Barker DJ, Pompoco C, Taylor S, Conley M, Patil A, Amakiri N, Stagg B, Ritch R, Kang JH, Wiggs JL, Curtin K, Wirostko B (2022). Association of Non-Melanoma Skin Carcinomas and UV Exposure with Exfoliation Syndrome in Utah. Med Res Arch, 10(10).
    8. Guidoboni G, Nunez R, Keller J, Wikle C, Robinson EL, Verticchio A, Siesky B, Oddone F, Quaranta L, Wirostko B, Topouzis F, Cheng C-Y, Januleviciene I, Wegner A, Antman G, Jones C, Harris A (2022). Precision medicine and glaucoma management: how mathematical modeling and artificail intelligence help in clinical practice. Online Journal. Expert Rev Ophthalmol, 17(5).
    9. Patil A, Swiston C, Wallace RT, Paulson C, Conley ME, McCoy L, Chaya C, Wirostko B (2022). Exfoliation Syndrome and Exfoliation Glaucoma in the Navajo Nation. An ARVO publication. ARVO Annual Meeting Abstract Search and Program Planner, 63(7), 1641.
    10. Levin AM, McGlumphy EJ, Chaya CJ, Wirostko BM, Johnson TV (2022). The utility of home tonometry for peri-interventional decision-making in glaucoma surgery: Case series. Am J Ophthalmol Case Rep, 28, 101689. (Read full article)
    11. Wirostko BM, Curtin K, Taylor SC, Paulson C, Pompoco C, Besch BM, Ranjan R, Ritch R (2022). Risk of atrial fibrillation is increased in patients with exfoliation syndrome: the Utah project on exfoliation syndrome (UPEXS) . Acta Ophthalmol, 100(4).
    12. Huang JJ, Geduldig JE, Jacobs EB, Tai TT, Ahmad S, Chadha N, Buxton DF, Vinod K, Wirostko BM, Kang JH, Wiggs JL, Ritch R, Pasquale LR (2022). Head and Neck Region Dermatological Ultraviolet-Related Cancers are Associated with Exfoliation Syndrome in a Clinic-Based Population . Ophthalmol Glaucoma, 5(6), 663-671.
    13. Pervan-Steel CL, Chowdhury UR, Sookdeo HK, Casale RA, Dosa PI, Htoo TM, Fautsch MP, Wirostko BM (2022). Ocular Hypotensive Properties and Biochemical Profile of QLS-101, a Novel ATP-Sensitive Potassium (KATP) Channel Opening Prodrug. Invest Ophthalmol Vis Sci, 63(4), 26.
    14. Sharma A, Riaz KM, Gill MS, Patnaik A, Ulahannan SV, Wang JS, Gombos DS, Ang Q, Cicic D, Bergonio GR, Zhang C, Wirostko BM (2021). Reversible HER2 antibody-drug conjugate-induced ocular toxicity. Can J Ophthalmol, 57(2), 118-126. (Read full article)
    15. Paulson C, Thomas SC, Gonzalez O, Taylor S, Swiston C, Herrick JS, McCoy L, Curtin K, Chaya CJ, Stagg BC, Wirostko BM (2022). Exfoliation Syndrome in Baja Verapaz Guatemala: A Cross-Sectional Study and Review of the Literature. J Clin Med, 11(7). (Read full article)
    16. Pompoco CJ, Curtin K, Taylor S, Paulson C, Shumway C, Conley M, Barker DJ, Swiston C, Stagg B, Ritch R, Wirostko BM (2021). Summary of Utah Project on Exfoliation Syndrome (XPEXS): Using a large database to identify systemic comorbidities . BMJ Open Ophthalmol, 6(1), e000803.
    17. Levin AM, Chaya CJ, Kahook MY, Wirostko BM (2021). Intraocular Pressure Elevation Following Intravitreal Anti-VEGF Injections: Short and Long-term Considerations. J Glaucoma, 30(12), 1019-1026.
    18. Levin AM, Vezina D, Wirostko BM (2021). Home-Based Intraocular Pressure Measurements: Tracing a Parallel with Out-of-Office Blood Pressure Measurement. Ophthalmol Glaucoma, 4(3), 235-237.
    19. Stagg BC, Stein JD, Medeiros FA, Wirostko B, Crandall A, Hartnett ME, Cummins M, Morris A, Hess R, Kawamoto K (2020). Special Commentary: Using Clinical Decision Support Systems to Bring Predictive Models to the Glaucoma Clinic. Ophthalmol Glaucoma, 4(1), 5-9. (Read full article)
    20. Stagg BC, Stein JD, Medeiros FA, Wirostko B, Crandall A, Hartnett ME, Cummings M, Morris A, Hess R, Kawamoto K (2020). Special Commentary: Using Clinical Decision Support Systems to Bring Predictive Models to the Glaucoma Clinic. Ophthalmol Glaucoma, 4(1), 5-9.
    21. Kang JH, VoPham T, Laden F, Rosner BA, Wirostko B, Ritch R, Wiggs JL, Qureshi A, Nan H, Pasquale LR (2021). Cohort Study of Nonmelanoma Skin Cancer and the Risk of Exfoliation Glaucoma. J Glaucoma, 29(6), 448-455. (Read full article)
    22. Wirostko B, Mann B, Stirland D (2020). Re: "Cross-Linked Hyaluronic Acid as Tear Film Substitute" by Posarelli et al. ( J Ocul Pharmacol Ther 2019;35(7):381-387) . J Ocul Pharmacol Ther, 36(4), 205.
    23. Perez VL, Wirostko B, Korenfeld M, From S, Raizman M (2019). Ophthalmic Drug Delivery Using Iontophoresis: Recent Clinical Applications. J Ocul Pharmacol Ther, 36(2), 75-87. (Read full article)
    24. Taylor SC, Bernhisel AA, Curtin K, Allingham RR, Ritch R, Wirostko BM (2018). Association between Chronic Obstructive Pulmonary Disease and Exfoliation Syndrome: The Utah Project on Exfoliation Syndrome. Ophthalmol Glaucoma, 2(1), 3-10. (Read full article)
    25. Besch BM, Curtin K, Ritch R, Allingham RR, Wirostko BM (2018). Association of Exfoliation Syndrome With Risk of Indirect Inguinal Hernia: The Utah Project on Exfoliation Syndrome. JAMA Ophthalmol, 136(12), 1368-1374. (Read full article)
    26. Wirostko B, Allingham R, Wong J, Curtin K (2018). Utah Project on Exfoliation Syndrome (UPEXS): Insight Into Systemic Diseases Associated With Exfoliation Syndrome. J Glaucoma, 27 Suppl 1, S75-S77. (Read full article)
    27. Durrie DS, Wolsey D, Thompson V, Assang C, Mann B, Wirostko B (2018). Ability of a new crosslinked polymer ocular bandage gel to accelerate reepithelialization after photorefractive keratectomy. J Cataract Refract Surg, 44(3), 369-375. (Read full article)

    Editorial

    1. Johnson C, Pasquale LR, Wirostko B (2024). Glucagon-Like Peptide 1 Receptor Agonists: A Role in Glaucoma? Ophthalmol Glaucoma. (Read full article)
    2. Mai AP, Wirostko B, Fitch S, Hansen K, Imbrescia W, Stagg BC (2023). Using Technology to Address Ophthalmic Technician Shortages in Glaucoma Clinics. Ophthalmol Glaucoma. (Read full article)

    Letter

    1. Delsoz M, Raja H, Madadi Y, Tang AA, Wirostko BM, Kahook MY, Yousefi S (2024). A Response to: Letter to the Editor Regarding "The Use of ChatGPT to Assist in Diagnosing Glaucoma Based on Clinical Case Reports.". [Letter to the editor]. Ophthalmol Ther. (Read full article)
    2. Wirostko B, Mann B, Stirland D (2020). Re: "Cross-Linked Hyaluronic Acid as Tear Film Substitute" by Posarelli et al. (J Ocul Pharmacol Ther 2019;35(7):381-387). [Letter to the editor]. J Ocul Pharmacol Ther, 36(4), 205. (Read full article)

    Abstract

    1. Amakiri N, Branham K, Jayasundera TK, Andrews, Chris A, Milentijevic D, Narayanan D, Johnson T, Jensen J, Wirostko BM, Stein JD (2023). Leveraging the Sight Outcomes Research Collaborative (SOURCE) Repository to Identify Patients with RPGR-Related Retinitis Pigmentosa  [Abstract]. 64(8), 4664.
    2. Chang M, Harris A, Zaid M, Sala L, Szopos M, Lapin S, Kuvin J, Ciulla TA, Pasquale LR, Wirostko BM, Verticchio V, Alice C, Antman G, Siesky BA, Guidoboni G (2023). The Impact of reduced left ventricular contractility on retinal perfusion, ARVO 2023 [Abstract]. 64(8), 1997.
    3. Kellner, R, Harris A, Rosen RB, Wirostko BM, Siesky BA, Verticchio V, Alice C, Coleman-Beli JC, Tessone I, Chang M, Fabczak-Kubicka A, Antman G (2023). Non-glaucomatous persons with diabetes have reduced macular capillary density potentially elevating the risk for glaucoma [Abstract]. 64(8), 4721.
    4. Kazemi A, Wirostko B, Fautsch M, Htoo T, Sit AJ (2023). Diurnal Variations in Episcleral Venous Pressure  [Abstract]. 64(8), 3473.
    5. Johnson T, Wirostko B, Stein J, Stagg B, Amakiri N, Jensen J (2023). Understanding the Disease Course of RPGR-Linked vs. RP2-Linked Retinitis Pigmentosa, ARVO 2023 [Abstract]. 64(8), 4667.

    Other

    1. (2023). Glaucoma Under Pressure, The Ophthalmologist July/August 2023. The Ophthalmologist.

    Patent

    1. Wiroskto, Barbara for Jade Therapeutics, LLC (2013). Ocular Drug Delivery System - including a composition in which a formulation having an active agent (e.g. HDH,rHGH or an HDH mimic) that increases insulin growth factor (IGF) or that alters insulin grouwth factor binding protein (IGFBP) in a subject is dispersed in a pharmaceutical carrier. The composition is configured for placement in, around or on an eye of the subject, and the composition provides controlled release of an amount of the active agent to the eye effective to promote ocular surface and corneal neural regeneration and wound healing. U.S. Patent No. WO/2013/158661 (PCT/US2013/036807). Washington, D.C.:U.S. Patent and Trademark Office.
    2. Wirostko, Barbara for Jade Therapeutics (2013). Application #4-HGH for Ocular Diseases. U.S. Patent No. 61/956,070. Washington, D.C.:U.S. Patent and Trademark Office.
    3. Wirostko, Barbara for Jade Therapeutics, LLC (2012). Application #2 - Dermal Wound Healing. U.S. Patent No. 61/58, 1845. Washington, D.C.:U.S. Patent and Trademark Office.
    4. Wirostko, Barbara for Jake Therapeutics (2012). Application #3 -Corneal Re-Innervation. U.S. Patent No. 3246-005. Washington, D.C.:U.S. Patent and Trademark Office.
    5. Wirostko, Barbara for Jade Therapeutics, LLC (2011). Application #1- Corneal Wound Healing. U.S. Patent No. 61/62,4730. Washington, D.C.:U.S. Patent and Trademark Office.

  • News & Podcasts

    News